Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $30,073 | $37,433 |
| General and administrative | 11,294 | 9,975 |
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s R&D?
- Kyverna Therapeutics, Inc. (KYTX) reported R&D of $30.07M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s R&D changed year-over-year?
- Kyverna Therapeutics, Inc.'s R&D decreased by 19.7% year-over-year, from $37.43M to $30.07M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s R&D?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s R&D has grown at a 63.7% compound annual growth rate (CAGR), from $49.92M to $133.72M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Kyverna Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude